Interpace Diagnostics is a health care commercialization company providing insight-driven, integrated multi-channel message delivery for health care companies. The Company is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

Type
Public
HQ
Parsippany-Troy Hills, US
Founded
1987
Size (employees)
61 (est)
Interpace Diagnostics was founded in 1987 and is headquartered in Parsippany-Troy Hills, US
Report incorrect company information

Interpace Diagnostics Office Locations

Interpace Diagnostics has an office in Parsippany-Troy Hills
Parsippany-Troy Hills, US (HQ)
300 Interpace Pkwy
Show all (1)
Report incorrect company information

Interpace Diagnostics Financials and Metrics

Interpace Diagnostics Financials

Interpace Diagnostics's revenue was reported to be $13.09 m in FY, 2016 which is a 38.7% increase from the previous period.
USD

Revenue (Q2, 2017)

3.9 m

Gross profit (Q2, 2017)

2 m

Gross profit margin (Q2, 2017), %

51.3%

Net income (Q2, 2017)

(6.3 m)

EBIT (Q2, 2017)

(3.6 m)

Market capitalization (2-Oct-2017)

27 m

Closing share price (2-Oct-2017)

1.2

Cash (4-Feb-2018)

14.3 m
Interpace Diagnostics's current market capitalization is $27 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

150.8 m119.9 m9.4 m13.1 m

Revenue growth, %

(20%)(92%)39%

Cost of goods sold

126.4 m101.4 m6.9 m6.6 m

Gross profit

24.4 m18.5 m2.5 m6.4 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

32.8 m31.6 m29.2 m38.3 m36.3 m36.6 m3 m3.6 m3.3 m3.5 m3.9 m

Cost of goods sold

27.7 m26.8 m25.5 m30.7 m30.2 m29.4 m1.2 m1.8 m1.8 m1.8 m1.9 m

Gross profit

5.1 m4.8 m3.7 m7.6 m6.1 m7.2 m1.9 m1.8 m1.5 m1.7 m2 m

Gross profit Margin, %

16%15%13%20%17%20%61%49%44%49%51%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

45.6 m23.1 m8.3 m602 k

Accounts Receivable

2.4 m8.5 m2.8 m2.2 m

Current Assets

62.7 m44.9 m19.2 m4.2 m

PP&E

2.8 m3.2 m1.5 m929 k
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

37.9 m35.6 m27 m17 m14.4 m9 m4.3 m3 m1.7 m7.1 m14.3 m

Accounts Receivable

8.5 m3.8 m3.4 m13.4 m11.9 m12.3 m2.8 m3 m2.8 m2.3 m2.7 m

Current Assets

59 m53.2 m42.2 m43.1 m39.3 m32.1 m11.7 m9.6 m6.7 m10.7 m18.3 m

PP&E

2.8 m2.8 m2.9 m3.3 m3.1 m2.8 m1.3 m1.2 m1.1 m770 k644 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(4.6 m)(16.1 m)(11.4 m)(8.3 m)

Depreciation and Amortization

4.5 m

Accounts Payable

143 k

Cash From Operating Activities

(3.5 m)(16.4 m)(19.8 m)(8.9 m)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(1.6 m)(2.7 m)(4.3 m)(3.9 m)(7 m)(4.9 m)(4.8 m)(2.3 m)(7.5 m)2.4 m(3.9 m)

Depreciation and Amortization

972 k1.9 m

Accounts Payable

2.1 m2.9 m3 m4.4 m4.5 m1.2 m1.3 m1.4 m295 k

Cash From Operating Activities

(4.1 m)(8.7 m)
USDY, 2017

Financial Leverage

1.5 x
Show all financial metrics

Interpace Diagnostics Operating Metrics

Interpace Diagnostics's Patent Applications was reported to be 16 in FY, 2016.
FY, 2016

Facilities

2

Patent Applications

16

Patents (US)

1

Patents (foreign)

3
Show all operating metrics
Report incorrect company information